Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease

Core Insights - Regeneron Pharmaceuticals, Inc. is considered one of the most undervalued stocks on NASDAQ, particularly following the positive results of its experimental medicine garetosmab in a phase 3 trial for fibrodysplasia ossificans progressiva [1][2] - The OPTIMA trial demonstrated that garetosmab significantly reduced new bone lesions by 90% or more compared to a placebo after 56 weeks [2] - The company plans to submit garetosmab for regulatory approval in the US by the end of 2025, with global submissions anticipated for the following year [2] Company Overview - Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on discovering, developing, and commercializing medicines for various diseases, including cancer, eye disorders, and allergies [3]